about
A new WNT on the bone: WNT16, cortical bone thickness, porosity and fracturesTLR5, a novel mediator of innate immunity-induced osteoclastogenesis and bone lossVasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors.SNX10 gene mutation leading to osteopetrosis with dysfunctional osteoclasts.Expression and regulatory role of receptors for vasoactive intestinal peptide in bone cells.Retinoid receptors in bone and their role in bone remodeling.Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclast differentiation in an LXRβ-dependent mechanismOsteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fracturesPorphyromonas gingivalis Stimulates Bone Resorption by Enhancing RANKL (Receptor Activator of NF-κB Ligand) through Activation of Toll-like Receptor 2 in Osteoblasts.Toll-Like Receptor 2 Stimulation of Osteoblasts Mediates Staphylococcus Aureus Induced Bone Resorption and Osteoclastogenesis through Enhanced RANKL.The gut microbiota regulates bone mass in miceThe bone-sparing effects of estrogen and WNT16 are independent of each otherEstrogen receptor-α is required for the osteogenic response to mechanical loading in a ligand-independent manner involving its activation function 1 but not 2.IL-4 and IL-13 inhibit IL-1β and TNF-α induced kinin B1 and B2 receptors through a STAT6-dependent mechanism.Vitamin a metabolism, action, and role in skeletal homeostasis.Kinin B1 and B2 receptor expression in osteoblasts and fibroblasts is enhanced by interleukin-1 and tumour necrosis factor-alpha. Effects dependent on activation of NF-kappaB and MAP kinases.The WNT system: background and its role in bone.Retinoids stimulate periosteal bone resorption by enhancing the protein RANKL, a response inhibited by monomeric glucocorticoid receptor.Inhibition of lipopolysaccharide-induced osteoclast formation and bone resorption in vitro and in vivo by cysteine proteinase inhibitors.Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2.Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.Establishment and validation of an in vitro co-culture model to study the interactions between bone and prostate cancer cells.Retinoids inhibit differentiation of hematopoietic osteoclast progenitors.High plasma osteocalcin is associated with low blood haemoglobin in elderly men: the MrOS Sweden Study.Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression.The neuropeptide VIP potentiates IL-6 production induced by proinflammatory osteotropic cytokines in calvarial osteoblasts and the osteoblastic cell line MC3T3-E1.TNF-alpha gene polymorphism and plasma TNF-alpha levels are related to lumbar spine bone area in healthy female Caucasian adolescents.Characterization of bradykinin receptors in a human osteoblastic cell line.Bacteria inhibit biosynthesis of bone matrix proteins in human osteoblasts.Helodermin, helospectin, and PACAP stimulate cyclic AMP formation in intact bone, isolated osteoblasts, and osteoblastic cell lines.Parathyroid hormone is able to enhance cyclic adenosine monophosphate formation without causing an increase in cytoplasmic Ca2+ in osteoblasts.Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells.Effects of parathyroid hormone on cyclic AMP-formation and cytoplasmic free Ca2+ in the osteosarcoma cell line UMR 106-01.Bradykinin induces formation of inositol phosphates and causes an increase in cytoplasmic Ca2+ in the osteoblastic cell line MC3T3-E1.Thrombin increases cytoplasmic Ca2+ and stimulates formation of prostaglandin E2 in the osteoblastic cell line MC3T3-El.Evidence for BK1 bradykinin-receptor-mediated prostaglandin formation in osteoblasts and subsequent enhancement of bone resorption.Effects on osteoclast and osteoblast activities in cultured mouse calvarial bones by synovial fluids from patients with a loose joint prosthesis and from osteoarthritis patients.Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.Monoclonal antibodies against the putative divalent cation-receptor that is located on parathyroid cells do not stain isolated rat osteoclasts.Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
P50
Q27009420-2B313DC0-6545-4E27-A35C-08F975150831Q28265502-DEB16C82-CDC3-4923-987E-877FD6AF8AF1Q31806478-63B69A44-3BF5-40E7-8EDD-0E7B59952ED6Q33774319-48D3C694-F962-4DD8-8D31-01D00435F93CQ34804000-62882E04-EDA4-4CB3-926A-9789EB46F135Q35167063-280C0CDB-13A3-401E-A7D8-C07DBD36D297Q35312616-DAF2B0F2-1246-44BB-8595-DF3184BBC5F8Q35360217-86EE14FF-2170-47C1-A652-50F731BF3417Q35953079-3CD79198-0583-4F0E-A628-DB9AB659F56EQ36054527-B244355B-78A7-4E4A-918E-444E5F1A59FFQ36153190-646EC2B7-552C-496C-B2B4-93D950BE33FFQ36354870-900E6791-1F8E-491E-9364-E42A22F5B387Q36619427-4B9E5D35-8957-4895-A8E0-F3374A5D5703Q36836381-E55F922B-78A1-4059-A623-C97E73397D3BQ38110518-5D2D7DD7-8963-46BA-A8CC-E08A60A07CA9Q38291148-0D32D8CA-DEED-4B5E-AC23-4DCB05147D88Q38407357-C82AB883-2269-40E1-B008-5A33DFD701D9Q38418725-4DA38563-3C6C-4EFE-B2C2-F6A6C140B01BQ38961652-5600E959-4145-475F-963F-E19D2B7C2508Q39270405-DFBE12A7-DE70-4156-987F-937893CA3059Q39421114-E93576EB-AFE2-4237-A173-384037BBB7C5Q39804089-2EACBC63-7D88-4C65-9F6D-1FF1661F4F0BQ39834688-B8264761-F89A-4AFE-A301-C1627495DDD8Q39869862-3782EF7F-40CD-46E1-9CDA-87A39B6E5A11Q40165573-6ABD02B1-D8F7-4C80-A4F2-C672DF59A500Q40386317-DBD18157-6DD7-471E-AAED-01B25A639EF6Q40643816-B972C132-EACD-4213-A02D-EF3FD8ED09ADQ40764725-18BBCD2D-B258-420F-B54D-D8533D06CB14Q41044972-5F6DCCC6-328E-46D3-B219-80A08D35ABB8Q41478191-5666E8DD-820D-4935-AAB0-DD8F98EFF11AQ41535191-77554EFB-6BE6-40D7-8FE2-C078211787E9Q41605798-3796494D-D53B-4ED7-B047-5EA8C44A9098Q41622743-5C97A0E2-FA3C-444E-9BA5-6F7403EC3551Q41686887-8031B30A-41F0-4D24-A5FA-925F0F7833F3Q41696285-CE1DAFCB-D3CA-4748-A0A7-54F28DE7F6B1Q41915691-1E262FDF-4D61-43E3-B35C-AB54E8A5913EQ42115715-65957205-99B3-4944-AB54-835340FA1BEFQ42248557-60903B12-756C-4ACF-9F35-837011F2A315Q42476343-2A97F8EB-A160-44C6-A2D5-885857ACAD87Q42489602-DE1FDF57-3D4E-40B0-A15D-173449EEAE97
P50
description
Zweeds onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ulf H Lerner
@ast
Ulf H Lerner
@en
Ulf H Lerner
@es
Ulf H Lerner
@nl
Ulf H Lerner
@sl
type
label
Ulf H Lerner
@ast
Ulf H Lerner
@en
Ulf H Lerner
@es
Ulf H Lerner
@nl
Ulf H Lerner
@sl
prefLabel
Ulf H Lerner
@ast
Ulf H Lerner
@en
Ulf H Lerner
@es
Ulf H Lerner
@nl
Ulf H Lerner
@sl
P106
P21
P27
P31
P496
0000-0002-3579-1960